Pharmacogenomic importance of pravastatin.
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly prescribed to reduce risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the interindividual variation in the response to pravastatin. This article reviews the most important studies conducted on the pharmacogenetics of pravastatin. Currently there is no evidence to advocate pharmacogenetic testing before initiating therapy.
Peters
Bas
B
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, The Netherlands.
Maitland-van der Zee
Anke-Hilse
AH
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014644:Genetic Variation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D017035:Pravastatin / Q000494:pharmacology* / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin